Syntax Bio, a synthetic biology company programming the next generation of cell therapies, has published new research in ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...

Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...

Goldenberries taste like a cross between pineapple and mango, pack the nutritional punch of a superfood, and are increasingly ...

A study identified two key genes (CTNNA1 and BCL2L13) as suppressors in spread of colorectal cancer, revealing new strategies ...

India's GenAI infrastructure is being built, but can a public-private partnership outpace the trillion-dollar budgets of US ...

The launch of BIRSA 101 marks a major breakthrough in CRISPR gene-editing technology, positioning India to deliver affordable ...

CRISPR technology, a revolutionary tool in genetic engineering, has empowered Lambert's iGEM team to tackle a significant health issue: Lyme disease, which affects nearly half a million Americans ...

CRISPR screens often mislead cancer research because bacterial Cas9 components trigger immune reactions in mice. ETH Zurich researchers developed a “stealth” CRISPR approach that removes immunogenic ...

Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of new research in Science Advances detailing the company’s CRISPR-based ...

Researchers used CRISPR to change the number of chromosomes in Arabidopsis by fusing chromosome arms, reducing the genome ...